Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 2/20 | 0.55 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 9/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16146679 | 0.83 | GDA (0.55) | MGMTGDABRAF | |
| SCHEMBL31506448 | 0.83 | GDA (0.55) | GDABRAF | |
| SCHEMBL16146528 | 0.83 | GDA (0.55) | MGMTGDABRAF | |
| SCHEMBL750335 | 0.83 | GDA (0.55) | GDABRAF | |
| SCHEMBL5694222 | 0.83 | GDA (0.55) | MGMTGDABRAF | |
| SCHEMBL16146215 | 0.82 | GDA (0.54) | MGMTGDABRAFHDAC1CDK2 | |
| SCHEMBL16146725 | 0.82 | GDA (0.54) | MGMTGDABRAFHDAC1HDAC2 | |
| SCHEMBL16145715 | 0.82 | GDA (0.54) | MGMTGDABRAF | |
| SCHEMBL5694220 | 0.82 | XDH (0.65) | GDABRAF | |
| SCHEMBL16145843 | 0.81 | GDA (0.52) | MGMTGDABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-115052986-A | Compositions comprising nucleases and uses thereof | 阿伯生物技术公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-113661242-A | Compositions comprising modified cyclic polyribonucleotides and uses thereof | 旗舰创业创新第六有限责任公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113543770-A | Compositions, methods and kits for delivery of polyribonucleotides | 旗舰创业创新第六有限责任公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113543766-A | Polyribonucleotides and their cosmetic use | 旗舰创业创新第六有限责任公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113453707-A | RNA for malaria vaccine | 库瑞瓦格股份公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-111819185-A | Compositions comprising cyclic polyribonucleotides and uses thereof | 旗舰创业创新第六有限责任公司 | 2020-10-23 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| EP-1525209-B1 | 1'-, 2'- AND 3' -MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-7662798-B2 | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | MGMT 3321/4885GDA 1170/4885DPP4 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.